Mascha Binder, MD, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, discusses the prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma under HER2 blockade and immune checkpoint therapy. The data generated in the Phase II INTEGA (NCT03409848) trial demonstrated the prognostic potential of circulating tumor DNA (ctDNA) both at baseline and following treatment. The complete cell-free DNA (cfDNA) content was correlated with clinical outcomes, demonstrating a significant in cfDNA between responders, non-responders and long-term responders. Prof. highlights the multifaceted use of liquid biopsy, which may also be used as a predictive tool for clinical decision making. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.